December 13(Sun) - 16(Wed), 2020
Karuizawa, Nagano, Japan

Chair: Koichi Ichimura

Vice Chair: Ryo Nishikawa

Venue: Karuizawa Prince Hotel West

Meeting ProgramDecember 13(Sun) - 16(Wed), 2020
Karuizawa, Nagano, Japan

Chair: Koichi Ichimura

Vice Chair: Ryo Nishikawa

Venue: Karuizawa Prince Hotel West

Program1

Contents
Welcome Message

4

Committees

5

Conference Information

7

ISPNO 2020 Award Recipients

11

Main Program (On Site & Live Streaming Program)

14

On-demand Program

27

Sponsors

28

3

Welcome Message
Dear Friends and Colleagues,
It is our great pleasure to welcome you to The 19 th International
Symposium on Pediatric Neuro-Oncology (ISPNO 2020). We aretremendously honored to host ISPNO, 35 years after the very first
ISPNO was held in Japan.
The COVID-19 pandemics have changed the world in 2020. It has
profoundly aﬀected our way of living and activities. Nonetheless, it will
not stop our science. ISPNO 2020, originally planned in June, is now
held in December at Karuizawa Prince Hotel West as a hybrid meeting. It
is a great opportunity for everyone to join the symposium from home orworkplace without having to travel!
We have a fantastic line-up of 82 invited lecturers who will give a live
talk and Q&A in the Main Program, which will be live streamed. The live
streaming contents will be posted in the On-Demand Program after the
symposium. In the On-Demand Program, all 858 accepted abstracts and
12 Education Day lectures will be made viewable from December 13,
2020 until February 13, 2021 for all registrants. In addition, we have

Koichi Ichimura, M.D., Ph.D.
Chair of ISPNO2020
Chief
Division of Brain Tumor
Translational Research
National Cancer Center
Research Institutelaunched the ISPNO Award scheme to recognize the long-standing
contribution of people who devoted their life for the development ofpediatric neuro-oncology.
My special thanks to Joan Slaughter of the Morgan Adams Foundation
who gave me invaluable advice on fundraising, and to Linda Greer of
the Society for Neuro-Oncology whose devotion was truly inspirational.
We thank all invited lecturers who agreed to give live online lectures
despite the time diﬀerence and all Education Day lecturers and abstract
authors who stuck with us upon the change of the format. We thankProf. Kamibeppu and Dr. Sato for organizing the nursing session, Ms.
Moue and Mr. Yamashita for organizing the Family Day, and all NPOs,
industries, The Rotary Club and individual donors who made thisincredible endeavor possible despite the unprecedented circumstances.
Last but not least, we thank the members of staff who helped us
throughout the preparation and the symposium.
Together, we will move pediatric neuro-oncology forward. Enjoy the
Symposium!

4

Ryo Nishikawa, M.D., Ph.D.
Vice Chair of ISPNO2020
Professor
Department of Neuro-Oncology/
Neurosurgery
Saitama Medical University
International Medical Center

Committee
ISPNO2020 Organizing Committee❖ Honorary Chairs❖ Vice Chair

Kintomo Takakura ✝

Ryo Nishikawa

Professor Emeritus, The University of Tokyo

Professor, Department of Neuro-Oncology/Neurosurgery✝ In Memory

Saitama Medical University International Medical Center

Masao Matsutani❖ Nursing Session Chair

Professor Emeritus, Saitama Medical University

Kiyoko Kamibeppu

Director, Gotanda Rehabilitation Hospital

Professor, Department of Family Nursing, Division of
Health Sciences and Nursing,Takamasa Kayama

Graduate School of Medicine, The University of Tokyo

Past-President, Japan Neurosurgical Society
President Emeritus, National Cancer Center Hospital❖ Secretary General

Professor, Faculty of Medicine, Yamagata University

Keita Terashima
Head, Division of Neuro-Oncology, Children's Cancer

Hajime Arai
Executive President, Japan Neurological Society
Professor and Chairman, Department of Neurosurgery
Faculty of Medicine, Juntendo University❖ Chair
Koichi Ichimura
Chief, Division of Brain Tumor Translational ResearchCenterNational Center for Child Health and Development❖ Deputy Secretary General
Tomonari Suzuki
Associate Professor, Department of Neuro-Oncology/
Neurosurgery
Saitama Medical University International Medical Center

National Cancer Center Research InstituteInternational Organizing Committee*In alphabetical order, by last name
❖ Chair

Steward Kellie (Australia)

Roger Packer (USA)Mark Kieran (USA)Chae-Yong Kim (Korea)❖ Members

Masao Matsutani (Japan)

Eric Bouﬀet (Canada)

Ludmila Papusha (Russia)

Sidnei Epelman (Brazil)

Stephan Pﬁster (Germany)

Nick Foreman (USA)Barry Pizer (UK)Amar Gajjar (USA)Stefan Rutkowski (Germany)

Richard Gilbertson (UK)

Chitra Sarkar (India)

Stewart Goldman (USA)

Irene Slavc (Austria)

Michael Handler (USA)Mark Souweidane (USA)Annie Huang (Canada)

Tai Tong Wong (Taipei)

Rakesh Jalali (India)

5

Committee
Local Organizing Committee*In alphabetical order, by last nameYoshiki Arakawa(Kyoto University)

Yozo Nakazawa(Shinshu University)

Akio Asai(Kansai Medical University)

Yoshitaka Narita(National Cancer Center Hospital)

Hiroshi Fuji

(National Center for Child Health

Atsushi Natsume(Nagoya University)and Development)

Sumihito Nobusawa(Gunma University)

Yukihiko Fujii(University of Niigata)

Hideki Ogiwara(National Center for Child Health

Takamitsu Fujimaki(Saitama Medical University Hospital)

Akira Gomi

(Jichi Medical University)

Hiroaki Sakamoto(Osaka City General Hospital)

Junichi Hara

(Osaka City General Hospital)

Hikaru Sasaki(Keio University)

Naoya Hashimoto(Kyoto Prefectural University of

Yuta Shibamoto(Nagoya City University)

Medicine)

Akira Shimada(Okayama University Hospital)

Yuichi Hirose(Fujita Health University)

Toshinori Soejima(Hyogo Cancer Center)

Tomotsugu Ichikawa(K a g a w a P r e f e c t u r a l C e n t r a l

Yukihiko Sonoda(Yamagata University Faculty of

Hospital)
Yonehiro Kanemura(National Hospital Organization
Osaka National Hospital)

Atsushi Kawamura(Hyogo Prefectural Kobe Children's
Hospital)

Katsuyoshi Koh(Saitama Children's Medical Center)

Yoshiyuki Kosaka(Hyogo Prefectural Kobe Children's
Hospital)

Toshihiro Kumabe(Kitasato University)

Katsuya Maebayashi(Nippon Medical School)

Kazuhiko Mishima(S a i t a m a M e d i c a l U n i v e r s i t y
International Medical Center)

Nobuhito Morota(Kitasato University School of
Medicine)

Akitake Mukasa(Kumamoto University)

Yoshihiro Muragaki(Tokyo Women's Medical University)

Motoo Nagane(Kyorin University)

Tatsuya Nagashima(Hyogo Prefecture Hospital)

Mitsutoshi Nakada(Kanazawa University)

Hideo Nakamura(Kurume University)and Development)

Medicine)
Kazuhiko Sugiyama(Hiroshima University)

Takashi Taga

(Shiga University)

Hideo Takeshima(University of Miyazaki)

Tetsuya Takimoto(National Center for Child Health

Takashi Tamiya(Kagawa University)

Tomoki Todo

(The Institute of Medical Science,and Development)

The University of Tokyo)
Yoshiyuki Tsutsumi(National Center for Child Health

Tetsuya Ueba

(Kochi Medical School)

Keisuke Ueki

(Dokkyo University)and Development)

Toshihiko Wakabayashi (Nagoya University)
Yuko Watanabe(National Cancer Center Hospital)

Tetsuya Yamamoto(Yokohama City University Hospital)

Takaaki Yanagisawa(Jikei University School of Medicine)

Koji Yoshimoto(Kagoshima University)

Secretariat of ISPNO 2020
c/o Convex Inc.
Toranomon Waiko Bldg., 5-12-1 Toranomon, Minato-ku, Tokyo 105-0001 Japan
Tel: +81-3-5425-1602 Fax: +81-3-5425-1605
E-mail: ispno2020@convex.co.jp

6Conference Information
Date:
December 13 (Sun) ‒ 16 (Wed), 2020
Venue: Karuizawa Prince Hotel West
Karuizawa-machi, Kitasaku-gun, Nagano
389-0193 Japan
Tel: +81-267-42-1111

Venue Map

7

Conference Information
Registration Desk

The Registration Desk is located at the banquet lobby of Karuizawa Prince Hotel West and is open during the following
hours:
December 13 (Sunday)
08:30-20:00
December 14 (Monday)
06:30-22:00
December 15 (Tuesday)
06:30-19:30
December 16 (Wednesday)
06:30-14:00

Registration Fee (For On-site only)
Category
Delegate 1

Price
JPY 70,000

Delegate 2/Student/Trainee/Healthcare Partner

JPY 30,000

Accompanying Person (Spouse, Family Member)

JPY

Gala Dinner

JPY 15,000

3,000*For Gala Dinner, seating is limited and on a ﬁrst-come, ﬁrst-served basis.

Payment Method

Payment must be made by credit card.
Accepted credit cards are VISA, MasterCard, Diners Club, AMEX, and JCB.

Name Badges and Program Book

You are requested to come to the Registration Desk to pick up your conference kit within the above time frame. The
name badge is mandatory for access to all sessions, social events and exhibitions during the conference.

Publication of Abstracts

All abstracts accepted for Oral and Poster Presentations at ISPNO 2020 will be available online and accessible from our
website. Scan the QR below to access E-Abstracts.
URL https://app.oxfordabstracts.com/events/1051/program-app/program

Internet AccessFree WiFi is available in the Karuizawa Prince Hotel West at the following places:+ Session Room
+ Lounge “KURUMI”+ LobbyCoﬀee BreakCoﬀee and snacks will be served at the lounge “KURUMI”. A drink counter with complimentary drinks will be set up.
There are power sockets available for use. Refresh and recharge while you observe the live sessions.

Lunch

Lunch boxes will be available at the Session Room during the following hours:
December 14 (Monday)
12:00-12:50
December 15 (Tuesday)
12:00-13:00
December 16 (Wednesday)
12:30-13:30

8

Conference Information
Social Events-Welcome Reception
Date: Sunday, December 13
Time: 18:00-20:00
Place: Chikuma, Karuizawa Prince Hotel West
Fee:
Included in the registration fee-Gala Dinner
Date: Tuesday, December 15
Time: 19:30-21:30
Place: Asama, Karuizawa Prince Hotel WestFee:
JPY 15,000*Seating is limited and on a ﬁrst-come, ﬁrst-served basis.

Safety and Security

Please do not leave valuable things unattended at any time, whether inside or outside session. We strongly recommendthat you use your hotel safety deposit box for your valuables.

Symposium Etiquette-

Participants are advised not to photograph or video and voice recording any sessions without the authorʼs consent.
Participants are also advised to obtain consent from authors before citing any of their work presented at the
symposium.
Switch your mobile phone to silent mode or turn it oﬀ completely during the sessions. Turn oﬀ the volume of otherelectronic devices such as, PC and DVD, and reduce screen brightness. We appreciate your cooperation.

Prevention Measures against COVID-19

1. If you have a fever or COVID-like symptoms, refrain from attending the symposium.
2. Wear your facemask.
3. Hand sanitizers are placed around the symposium venue. Clean and disinfect your hands thoroughly.
4. Follow the rules and regulations of the facility.
5. Air ventilation is important in preventing the coronavirus from spreading indoors; due to this, there might benoises and we apologize for the inconvenience.

Contact

Secretariat of ISPNO 2020
c/o Convex Inc.
Toranomon Waiko Bldg., 5-12-1 Toranomon, Minato-ku, Tokyo 105-0001 Japan
Tel: +81-3-5425-1602 Fax: +81-3-5425-1605
E-mail: ispno2020@convex.co.jp

Instructions for Presentation On-site

1. PC Preview Desk is located next to the Session Room.
2. Please bring your PC or presentation data (PPT) to the PC Preview Desk at least 30 minutes prior to yourpresentation to register and submit it to test the connection and view your ﬁle.
3. All presentations will be done on PC. Please use the following settings in PowerPoint for your presentation
slides:• 16:9 aspect ratio• Refrain from using Presenter View
4. For Windows users, please bring your presentation data in the form of CD-R or USB Flash memory; or your own
PC. For Macintosh users, please bring your own PC for your presentation.
5. PCs with Windows 10 and PowerPoint 2010, 2013 and 2016 are to be used.
6. If you are using your own PC, please conﬁrm whether your PC has an RGB port (mini D-sub 15 pin type) or
HDMI port to connect to the projector. If you use a diﬀerent type of RGB jack to connect to an external monitor,
please bring it with you. Please bring your PC charger and adapter in case the battery runs out during yourpresentation.

9

Conference Information
7. Please use the mouse on the podium for your presentation. You are required to handle your data yourself, using
the mouse connected to the PC.
8. The copied data for your presentation will be deleted by the secretariat after the symposium.

Disclosure of Conﬂicts of Interest (COI)

All presenters must declare their COI status on the ﬁrst presentation slide (or immediately after the title and presenters)
as shown in the example below:
e.g.1)ISPNO 2020
COI Declaration
Aﬃliation Name (all presenters)
The presenter has no conﬂict of interest with any corporate
organizations relating to this presentation.

e.g.2)ISPNO 2020
COI Declaration
Aﬃliation Name (all presenters)
The presenter has potential conflict of interest with thecorporate organizations below:
Name of organizations

10

ISPNO 2020 Award Recipients
Lifetime Achievement Award
Roger J. Packer, MD
It is with great enthusiasm that the members of the ISPNO community have decide to oﬀer this ﬁrst Lifetime Achievement
Award to Dr. Roger Packer.
Dr. Packer started his career in Philadelphia, in 1981. He very quickly became one of the leaders of this small communityof oncology specialists interested in pediatric brain tumors. Over the years, he came to inﬂuence the management of
most pediatric brain tumors, many of the protocols he developed being commonly referred to as the “Packer regimens”.
The description of Dr. Packerʼs multiple contributions to the field of pediatric neuro-oncology could span entire
chapters. He has been and still remains an active, passionate and dedicated member of the COG and several national orinternational networks, such as the Neuroﬁbromatosis Consortium or the Pediatric Brain Tumor Consortium. He is a true
leader and generates ideas that frequently translate into innovative protocols or national/international collaborations. As
we all know, Dr. Packerʼs career is also strongly associated with the story of the ISPNO meeting and he has contributed
to the development of an international paediatric neuro-oncology network.
Each and every member of the pediatric neuro-oncology community overwhelmingly shares the opinion that Dr Packerʼs
unparalleled contribution to his ﬁeld should be recognized at this time of his career and it is really a pleasure and aprivilege to oﬀer him this Award at the ISPNO Meeting 2020.

Award Recipient Proﬁle:Dr. Roger J. Packer is the Senior Vice President of the Center for Neuroscienceand Behavioral Medicine and Director of the Brain Tumor Institute and the Gilbert
Family Neurofibromatosis Institute at Children's National Hospital in Washington,
DC. His career is focused on the care of children with brain tumors including thedevelopment of prospective clinical trials for children with medulloblastoma, otherembryonal tumors, and with high and low-grade gliomas. He has and continues
to lead efforts in multiple brain tumor and neurofibromatosis consortiums andthe protocols Dr. Packer developed for medulloblastoma and low-grade glioma
remain international standards. He has published well over 400 original article and
350 chapters and books. He was one of the founders of ISPNO, co-chairing theﬁrst meeting in the United States in Seattle in 1989, while also chairing ISPNO in
Philadelphia (1990) and Washington, D.C. (1996).
Roger J. Packer, MD

11

ISPNO 2020 Award Recipients
Lifetime Contribution to Asian Neuro-Oncology
Community Award
Tai-Tong Wong, MD
Dr. Tai-Tong Wong represents one of the most senior and well-respected pediatric brain tumor specialist andneurosurgeon in Taiwan and Asia. He completed his undergraduate medical degree in 1973 from the NDMC and thenpursued neurosurgical training at Taipei VGH (1973-1978) followed by a pediatric neurosurgery fellowship at SickKids
Hospital, Canada (1980). He returned to Taiwan where he helped drive innovative multi-disciplinary approaches andpediatric brain tumor research and trained the ﬁrst generation of pediatric neuro-surgeons in Taiwan. Most recently(2015), he became the director of the pediatric brain tumor program of Taipei Cancer Center at TMUH/TMU where
he maintains a very busy consult service and directs a brain tumor research laboratory. Recently, he led and became
founding president of the Taiwan Pediatric Brain Tumor Consortium (TPBTC).
In addition to his home country, Dr Wong has also played a critical role in the development of pediatric neurosurgery andneuro-oncology in Asia through international training initiatives and leadership in multiple international organizations. In
addition to founding presidencies of TSNO (2003-2005), TSPN (2008-2010), he has served as president of ASPN (20152017) and ISPN (2009-2010). He has been an active organizer of multiple local and several international congresses
including the 4th Congress of ASNO (2005), the 34th ISPN annual meeting (2006), and 2nd Asian CNS GCT Conference(2016). The ISPNO 2020 Award for Lifetime contribution to Asian Neuro-Oncology Community recognizes the invaluable
career-long commitment of Dr Wong to promoting pediatric neuro-surgery and Neuro-oncology in Asia.

Award Recipient Proﬁle:Dr. Tai-Tong Wong is currently staﬀ and professor of pediatric neurosurgery anddirector of pediatric brain tumor program of Taipei Cancer Center at TMUH/TMU(since 2015). He graduated from NDMC (1973) and received neurosurgical andpediatric neurosurgical training in Taipei VGH (1973-1978) and HSC Toronto (clinicaland research fellow, 1980), respectively. He dedicates for team treatment andresearch of pediatric brain tumors since then. He has been the first president of
TSNO (2003-2005), TSPN (2008-2010), AASPN (2015-2017), TPBTC (2020-2023);
president of ISPN (2009-2010); and pediatric neurosurgery committee chairmanof WFNS (2010-2013). He had also hosted and organized international congresses
including the 4th Congress of ASNO (2005), the 34th ISPN annual meeting (2006),
and 2nd Asian CNS GCT Conference (2016).

Tai-Tong Wong, MD
Pediatric Brain Tumor Programand Pediatric Neurosurgery,
Department of Neurosurgery,
Taipei Medical University
Hospital

12

Abbreviations: TMUH ‒ Taipei Medical University Hospital; TMU ‒ Taipei Medical
University; NDMC ‒ National Defense Medical Center; Taipei VGH ‒ Taipei Veterans
General Hospital; HSC Toronto ‒ Hospital for Sick Children Toronto; TSNO ‒ Taiwan
Society for Neuro-Oncology; TSPN ‒ Taiwan Society for Pediatric Neurosurgery;
AASPN ‒ Asian Australasian Society for Pediatric Neurosurgery; WFNS ‒ World
Federation of Neurological Society; ASNO ‒ Asian Society for Neuro-Oncology; ISPN
‒ International Society for Pediatric Neurosurgery; CNS GCT ‒ Central Nervous
System Germ cell Tumor.

ISPNO 2020 Award Recipients
Pediatric Neuro-Oncology Community Service AwardAngela Dickson, MBE
Neil Dickson, MBE
Neil and Angela Dickson have made a signiﬁcant contribution to neuro-oncology in the last 24 years. Inspired by theloss of their beautiful daughter Samantha, and recognising that there was not enough research into brain tumours, they
worked tirelessly to ensure that high quality research was pursued across the UK, and around the world.
Among other achievements, theyʼve funded work that led to the discovery of the medulloblastoma subtypes, andsteadfastly supported Head Smart, the award winning campaign that decreased diagnosis time for UK children witha brain tumour and in 2012 were integral in the merger which formed The Brain Tumour Charity as a global funder of
research in the ﬁeld.

Award Recipient Proﬁle:Neil and Angela founded the Samantha Dickson Brain Tumour Trust in 1996, sincerenamed The Brain Tumour Charity. It is one of the largest funders of brain tumour
research in the World. Being passionate about International collaboration, they havebeen supporters of ISPNO, attended seven conferences and have been silver andgold sponsors. We are delighted to accept this Award from ISPNO in recognition of
our contribution towards helping ﬁnd a cure for brain tumours.

Angela Dickson, MBE
Founder Trustee, The Brain
Tumour Charity
Neil Dickson, MBE
Founder and Vice chair ofTrustee, The Brain Tumour
Charity13

Main Program(On Site & Live Streaming Program)
December 13 (Sunday)
9:00 - 11:20

9:00 - 9:05

Nursing Session

Introduction
Kiyoko Kamibeppu (Japan)

9:10 - 9:50

Education Support for Pediatric Brain Tumor Patients
Chie Matsuo (Japan)

9:50 - 10:00

Break

10:00 - 11:20

Cognitive Function and Education Support in each Country

10:00 - 10:25

Child and family concerns related to cognitive function after treatment for pediatric brain tumor
Naoko Takenouchi (Japan)

10:25-10:50

Supporting cognition and learning in pediatric brain tumor patients:
The role of executive functioning surveillance and intervention
Kristi Hardy (USA)

10:50 - 11:00

Commentary
Pamela S. Hinds (USA)

11:00 - 11:20

11:20 - 12:15
11:20 - 12:00

Discussion

Family Day Session
Pediatric Brain Tumor Patient Advocates in Japan
Yuko Moue (Japan)

12:00 - 12:15

Around the world in 15 minutes: innovative approaches to support, treatment and careof pediatric brain tumour patients
Kathy Oliver (UK)18:00 - 20:00

14

Welcome Ceremony

Main Program(On Site & Live Streaming Program)
December 14 (Monday)
7:00 - 8:00

7:00 - 7:20

Symposium 1 NGS - where do we go from here?

Learning from non-coding mutations in cancer genomes
Hiromichi Suzuki (Canada)

7:20 - 7:40

Developmental and oncogenic programs in pediatric ependymoma revealed bysingle-cell RNAseq
Mariella G. Filbin (USA)7:40 - 8:00

Context matters: Cell of origin dependencies in histone H3.3G34-mutant gliomas
Claudia Kleinman (Canada)

8:00 - 8:30

Opening Ceremony

Opening Performance
Kan Fukuhara (Japanese ﬂute), Soh Katada (Japanese percussion)
Opening Speech
Koichi Ichimura (Japan)

8:30 - 8:40

Award Ceremony 1 Lifetime Achievement Award

Presenter: Eric Bouﬀet (Canada)
Acceptance Speech
Roger Packer (USA)8:40 - 9:10

Opening Keynote Lecture

Pediatric neuro-oncology: perspectives of the new decade
Roger Packer (USA)9:10 - 10:00
9:10 - 9:25

Late-breaking Session Pediatric Neuro-Oncology and COVID-19
Characteristics of SARS-CoV-2 in 64 Children with CNS Tumors: A Report from the
SIOP/St. Jude Childrenʼs Research Hospital (SJCRH) Global COVID-19 Childhood
Cancer Registry
Eric Bouﬀet (Canada)

9:25 - 9:35

Vinblastine monotherapy induction for localised CNS germinoma during the COVID-19
pandemic
Matthew Murray (UK)9:35 - 9:45

Impact of COVID-19 on therapy provision for children with CNS tumours
Helen Hartley (UK)

9:45 - 10:00

Q&A

15

Main Program(On Site & Live Streaming Program)
10:00 - 10:30

Special Lecture 1

Genomics and Immunogenomics of Progression in Pediatric CNS Cancers
Elaine Mardis (USA)10:30 - 11:00

Special Lecture 2

Pediatric precision neuro-oncology: 2020 status reportWill Parsons (USA)
11:00 - 12:00

Sponsored Seminar 1

Targeted Therapy for CNS Tumors (STARTRK Trial)(No On-Demand Program)Amar Gajjar (USA)
12:00 - 12:50
12:00 - 12:40

Luncheon Seminar 1
Hands-on Experience Program for Pediatric Cancer Patients and Their Families:
Scan It! See through it! Seeing is exciting!
Akiko Higuchi (Japan)

12:40 - 12:50

Commentary
Kathy Oliver (UK)

12:50 - 13:00

Break

13:00 - 13:10

Award Ceremony 2
Lifetime Contribution to Asian Neuro-Oncology Community Award

Presenter: Annie Huang (Canada)
Acceptance Speech
Tai-Tong Wong (Taiwan)

16

Main Program(On Site & Live Streaming Program)
13:10 - 15:00
13:10 - 13:20

Forum 1 Pediatric Neuro-Oncology in Asia and other Countries
The global burden of childhood central nervous system (CNS) cancer
Jonathan Finlay (USA)

13:20 - 13:30

Pediatric Neuro-Oncology in China
Zhong-Ping Chen (China)

13:30 - 13:40

Clinical trial results and current treatment trends for medulloblastoma in Korea
Jung Woo Han (Korea)

13:40 - 13:50

TBA
Suradej Hongen (Thailand)

13:50 - 14:00

Paediatric Brain Tumors in a Tertiary Government Hospital in the Philippine Setting
Annabell Chua (Philippines)

14:00 - 14:10

Epidemiology, Treatment, and Outcomes of Medulloblastoma: The Indian Experience
Tejpal Gupta (India)

14:10 - 14:20

Diagnostic and treatment results of patients with brain tumors in D. Rogachev
National Medical Research CenterLudmila Papusha (Russia)

14:20 - 14:30

Free access for molecular diagnosis in medulloblastoma in Brazil and Latin America- preliminary results
Sidnei Epelman (Brazil)

14:30 - 14:40

Pediatric intracranial germ cell tumors and medulloblastoma; the Jordanian experience
Nisreen Amayiri (Jordan)

14:40 - 15:00

Panel Discussion and Wrap up
R. Nishikawa (Japan) /J. Finlay (USA) / G. Dhall (USA) / E. Bouﬀet (Canada) /U. Bartels (Canada)

15:00 - 15:30

Afternoon Seminar 1
Long-term Survivorship Challenges and Novel Mitigation Strategies inChildhood Brain Tumours

Preservation of cognition and neuro-psychological function after modern photon andproton beam irradiation for childhood CNS tumours
Rakesh Jalali (India)
15:30 - 16:00

Break

16:00 - 16:20

Keynote 1 Palliative Care
Pediatric Palliative Care
Nobuyuki Yotani (Japan)

17

Main Program(On Site & Live Streaming Program)
16:20 - 17:00

16:20 - 16:40

Symposium 2 Preclinical Model for Pediatric Brain Tumors

Human pluripotent stem cell-derived brain tumor model uncovers the embryonic stem
cell signature as a key driver in atypical teratoid/rhabdoid tumor
Yukinori Terada (Japan)

16:40 - 17:00

Future prospective in preclinical studies of pediatric brain tumors using mouse
molecular genetic technologies
Daisuke Kawauchi (Japan)

17:00 - 17:10

Award Ceremony 3 Pediatric Neuro-Oncology Community Service Award

Presenter: Barry Pizer (UK)
Acceptance Speech
Angela & Neil Dickson (UK)
17:10 - 17:40

Special Lecture 3

Will we ever cure cancer?
Richard Gilbertson (UK)
17:40 - 18:00

Symposium 3 Precision Medicine
PRECISION MEDICINE: the challenges beyond the discovery
Jacques Grill (France)

18:00 - 18:25

Keynote 2 Low Grade Glioma (basic)

Pediatric low-grade glioma: State-of-the-art in 2020
David Jones (Germany)
18:25 - 18:50

Keynote 3 HGG (basic)
The diversity of what we call a ʻhigh grade gliomaʼ in children and young adults
Chris Jones (UK)

18:50 - 19:15

Keynote 4 Ependymoma (basic)

Ependymoma, an increasingly less enigmatic disease18

Kristian Pajtler (Germany)

Main Program(On Site & Live Streaming Program)
19:15 - 19:40

Keynote 5 AT/RT
ATRT ‒ update on biology, subgroups, targets, and potential clinical implications
Marcel Kool (Germany)

19:40 - 21:30

Break

21:30 - 22:00

Special Lecture 4
PFA ependymoma ‒ a metabolic monster
Michael Taylor (Canada)

22:00 - 23:30
22:00 - 22:20

Forum 2 Preserving and Enhancing QoL and Function
Early global neurologic rehabilitation in pediatric patients with brain tumors
Andrés Morales La Madrid (Spain)

22:20 - 22:40

Practical tools for enhancing functional outcomes in neuro-oncology
Nathan Rosenberg (USA)22:40 - 23:00

Radiotherapy Methods to Preserve Quality of Life and Organ Function in PediatricCancer Patients
Joshua Palmer (USA)

23:00 - 23:20

Palliative Care approach to optimize function and quality of life on patients with brain tumor
Paola Genovese (USA)

23:20 - 23:30

Q&A

19

Main Program(On Site & Live Streaming Program)
December 15 (Tuesday)
7:00 - 7:25

Keynote 6 ETMR and other Embryonal Tumors
Understanding the clinical and biological landscape of ETMRs
Annie Huang (Canada)

7:25 - 7:50

Keynote 7 Craniopharyngioma
Treatment Challenges of Adamantinomatous Craniopharyngioma
Ute Bartels (Canada)

7:50 - 8:15

Special Lecture 5
Replication repair deﬁciency and hypermutation in childhood brain tumors:
Insights on germline and somatic mutagenesis
Uri Tabori (Canada)

8:15 - 8:40

Keynote 8 Low Grade Glioma (clinical)

Paediatric Low Grade Gliomas: clinical management
Eric Bouﬀet (Canada)
8:40 - 9:05

Keynote 9 DIPG
Molecular pathways and therapeutic opportunities in DIPG
Nada Jabado (Canada)

9:05 - 9:30

Keynote 10 HGG (clinical)

Translating the advancing biology of CNS high-grade gliomas into actual
patient beneﬁt
Mark Kieran (USA)9:30 - 9:55

Late-breaking Lecture Ependymoma ACNS0831 Clinical Trial

ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy inPatients with Newly Diagnosed Ependymoma Ages 1 to 21 years
Amy Smith (USA)20

Main Program(On Site & Live Streaming Program)
9:55 - 10:20

Keynote 11 Ependymoma (clinical)

Posterior Fossa Ependymoma (PF EPN): Reaching for Eﬀective Therapy
while exploring new Biology
Nicholas Foreman (USA)
10:20 - 10:45

Keynote 12
Pathology and Molecular Classiﬁcation (WHO Classiﬁcation and cIMPACT-NOW)

Histopathology and molecular pathology in the diagnosis of pediatric CNS
tumors - WHO Classiﬁcation, Edition 5
David Ellison (USA)10:45 - 11:10

Keynote 13 Epidemiology
Know the facts! An update on causes and risk factors for childhood brain tumors
Jill Barnholtz-Sloan (USA)11:10 - 11:50

Special Lecture 6

Neuroﬁbromatosis type 1
Murali Chintagumpala (USA)11:50 - 12:00

Break

12:00 - 13:00

Luncheon Seminar 2

Molecular pathogenesis and treatment of primary central nervous system lymphoma:
Evidence and perspectives(No On-Demand Program)

Motoo Nagane (Japan)

21

Main Program(On Site & Live Streaming Program)
13:00 - 14:20

13:00 - 13:30

CNS Germ Cell Tumors Session

Special Lecture 7(basic) Mechanism and In Vitro Reconstitution of Mammalian Germ-Cell Development
Mitinori Saitou (Japan)

13:30 - 13:55

Keynote 14(clinical) Treatment of CNS germ cell tumors, from the past to the future
Masao Matsutani (Japan)

13:55 - 14:20

Keynote 15(clinical) Korean studies in intracranial germ cell tumors
Chang-Ok Suh (Korea)

14:20 - 14:50

Special Lecture 8
Deciphering the origin of somatic mutations in brain tumors
Jeong Ho Lee (Korea)

14:50 - 15:20

Special Lecture 9
Japanese platform for cancer genomic medicine; a new hope for children
Hiroyuki Mano (Japan)

15:20 - 15:50

Afternoon Seminar 2 Nanopore Sequencing
Characterization of complicated structural variants with local copy-number changes incancer genomes using PromethION
Yutaka Suzuki (Japan)

15:50 - 16:20

Meet-the-Experts

Endoscopic endonasal resection of sellar and parasellar lesions for pediatric andadolescent patients
Yudo Ishii (Japan)

22

Main Program(On Site & Live Streaming Program)
16:20 - 17:10
16:20 - 16:45

Neurosurgery Session
Keynote 16
Overcoming the limitation of current treatment for malignant pediatric brain tumors:
updating neurosurgical points of views
Chae-Yong Kim (Korea)

16:45 - 17:10

Keynote 17
Surgical challenges and solutions for improving surgical outcome in Ependymoma
Surgery
Conor Mallucci (UK)

17:10 - 17:40

Special Lecture 10

Hereditary predisposition to childhood cancer
Stefan Pﬁster (Germany)
17:40 - 19:20
17:40 - 18:00

Forum 3 Posterior Fossa Syndrome
Symposium on cerebellar mutism syndrome
Barry Pizer (UK)18:00 - 18:20

Radiology of Cerebellar Mutism Syndrome
Shivaram Avula (UK)

18:20 - 18:40

Surgical aspects to minimise cerebellar mutism syndrome- have we made any progress?
Conor Mallucci (UK)

18:40 - 18:50“The Nordic-European study of the cerebellar mutism syndrome”‒ Establishing the Study
Astrid Sehested (Denmark)18:50 - 19:00

Cerebellar Mutism Syndrome and the surgical risk factors: a prospective multicentre
study of 500 patients undergoing tumour surgery in the posterior fossa
Jonathan Kjær Grønbæk (Denmark)19:00 - 19:10

Future Directions for Research in Cerebellar Mutism Syndrome
Astrid Sehested (Denmark)19:10 - 19:20

19:30 - 21:30

Panel discussion/Q&A

Evening Seminar

23

Main Program(On Site & Live Streaming Program)
December 16 (Wednesday)
7:00 - 7:20

Symposium 2 Preclinical Model for Pediatric Brain Tumors

Recapitulating developmental context using genetically engineered and patient-derived
models of pediatric diﬀuse high-grade gliomas
Suzanne Baker (USA)
7:20 - 7:40

Symposium 3 Precision Medicine
Precision Medicine in Pediatric Neuro-Oncology
Sabine Mueller (USA)7:40 - 8:00

Keynote 18 Preclinical models/Experimental Therapy/Drug Discovery

In Silico Drug Screening and System Biology Approach in Drug Repurposing
Ching Lau (USA)
8:00 - 8:20

Keynote 19 Pediatric Neuropsychology
Biological Substrates of Impaired Neurocognitive Functioning: Understanding the LateEﬀects of Surviving a Pediatric Brain Tumor
Stephen Sands (USA)8:20 - 9:30
8:20 - 8:40

Forum 4 Immunotherapy
Advances in cellular immunotherapy targeting pediatric brain tumors
Duane Mitchell (USA)8:40 - 9:00

Todayʼs immunotherapy for pediatric CNS tumors: brieﬂy deﬁning the Gordian Knot
Eugene Hwang (USA)

9:00 - 9:20

Nivolumab monotherapy and nivolumab in combination with ipilimumab in pediatricpatients with high-grade primary central nervous system malignancies: safety andPharmacokinetic results from CheckMate 908
Ira Dunkel (USA)

9:20 - 9:30

24

Panel discussion/Q&A

Main Program(On Site & Live Streaming Program)
9:30 - 10:20

9:30 - 9:55

Medulloblastoma Session

Keynote 20(basic) Medulloblastomics 2020: biological and clinical insights from 1,000s of patients
Paul Northcott (USA)9:55 - 10:20

Keynote 21(clinical) Medulloblastoma ‒ Biology informs Clinical Outcome
Amar Gajjar (USA)

10:20 - 10:40

Keynote 22 Drug Delivery
Convection enhanced delivery (CED) in the brain stem of children with diﬀuse intrinsic
pontine glioma (DIPG): beyond feasibility
Mark Souweidane (USA)

10:40 - 11:05

Special Lecture 11

Brain immunology and immunotherapy in brain tumors.
David Ashley (USA)
11:05 - 11:30

Keynote 23 Viral/gene Therapy

Results of phase II clinical trial of oncolytic herpes virus G47 Δ in adult patients with
Glioblastoma(No On-Demand Program)

Tomoki Todo (Japan)
11:30 - 11:50

Keynote 24 Radiation Oncology

Radiation Oncology in Pediatric Neuro-oncology
Thomas Merchant (USA)11:50 - 12:30

Keynote 25 Imaging

pH-weighted molecular imaging of brain tumors
Benjamin Ellingson (USA)25

Main Program(On Site & Live Streaming Program)
12:30 - 13:30

Luncheon Seminar 3 Epilepsy

Tumor-related epilepsy and long-term epilepsy associated tumors in children:
epilepsy surgeonsʼ perspective(No On-Demand Program)

Kensuke Kawai (Japan)
13:30 - 13:50

Closing Ceremony
Closing remarks
ISPNO2020 Award
Koichi Ichimura (Japan)

13:50 - 14:00

HandoverIntroduction to ISPNO2022 in Hamburg
Stefan Rutkowski (Germany)
Stefan Pﬁster (Germany)

14:00 - 14:10

26

Adjourn

On-demand Program
On-demand Program at ISPNO 2020 will be available online and accessible from the
URL and QR code below. The Main Program will be added and viewable after the
meeting in January 2021.
Viewing Period: December 13 (Sun), 2020 ‒ February 13 (Sat), 2021

URL: https://web-mice.jp/ispno2020/en/member/Login27

Sponsors
GOLD SPONSORSThe Morgan Adams Foundation

The Morgan Adams Foundation has funded pediatriccancer research since 1998, giving kids with cancer

and their families more than hope. Working with leading
researchers and physicians, we fund new and innovativeideas that will improve cancer treatment effectiveness,overall outcomes, survival rates and quality of life while
minimizing the devastating side eﬀects current treatments
have on children.

Powered by a cutting-edge multi room Proton Centre.
Apollo Proton Cancer Centre is revolutionizing radiation
oncology not just in India, but across the region. The
hospital is a beacon of hope for over 3.5 billion people.

Apollo Proton Cancer Centre
The Most Advanced Cancer Centre- First Proton Centre
in South Asia & The Middle East
The Apollo Proton Cancer Centre (APCC) is a 150bed integrated cancer hospital offers state-of-the-art
comprehensive cancer care. It is South Asia & the Middle
East's first Proton Therapy and a major milestone in
India's concerted focus to battle and conquer cancer.

The advanced Proton Therapy at Apollo Proton Cancer
Centre is complemented by a fully integrated treatment
suite that oﬀers the most advanced treatment proceduresin surgical, radiation, medical oncology. True to the Apollo
Pillars of Expertise and Excellence, the Centre brings
together a powerful medical team helmed by some of theinﬂuential names in cancer care.
At the bedrock of APCC's approach to treat cancer
is its robust multi-disciplinary platform; highly skilled
professionals - united by expertise and commitment come together to form Cancer Management Teams (CMT).
Each CMT is focused on delivering the best possible
outcomes to their patients.

patients and health care providers.
Weʼre working to create solutions that go beyond treating
the illness to have a positive impact on patientsʼ lives, on
societies̶and on science itself.
At AbbVie, we see a future of possibility, where health isin reach and patient lives are improved.
・175+ countries where our products help patients

AbbVie Inc.
AbbVie is a research-driven global biopharmaceuticalcompany headquartered in the United States.
At AbbVie, our mission is to have a remarkable impact
on peopleʼs lives. We are passionate about advancing
oncology research and development with an aim totransform standards of care for people living with cancer.
Together, we harness our pioneering spirit, the focus
and expertise of our team and partners, and cutting-edge
resources to accelerate the delivery of advancements to・~ 47,000 employees 14 countries with R&D andmanufacturing facilities
・60+ conditions treated・Focus Areas: Immunology, Oncology, Neuroscience,
Eye Care, Virology, Womenʼs Health, Gastroenterology,
Allergan Aesthetics
In Japan, more than 1,200 employees work at AbbVie.
Putting patients at the center of what we do, we
collaborate with stakeholders to address the challenges
facing healthcare today and tomorrow. We market our
products in focus therapeutic areas such as Immunology,
Neonatology, Hepatitis, Neuroscience and Oncology.

Bristol Myers Squibb

28

SponsorsChildren's Hospital Colorado
Registration fee (Category: Delegate 2) for clinicians,
researchers and industry members who are from the low/
lower-middle income countries assigned by the WorldBank Group are partially supported by the donations fromChildren's Hospital of Colorado.

The Robert Connor Dawes Foundation
The Robert Connor Dawes Foundation works closely withorganisations and researchers around the world to fasttrack research funding and ultimately, improve treatment
options.
We believe more brains are better than one, and we're
proud to fund crucial research collaborations including,
The AIM BRAIN Project, in partnership with ANZCHOG
and DKFZ in Germany, and a CERN Fellowship currently
underway in Cambridge.

SILVER SPONSORS

the Arnold & Winnie Palmer Foundation
The Arnold & Winnie Palmer Foundation champions
the legacy of our founders. Through grantmaking andinitiatives, we continue Arnold and Winnieʼs devotion to
youth ‒ encouraging strong character and supportingchildren facing health challenges ‒ and honor theircommitment to nature and its ability to enrich and heal us.

Chugai Pharmaceutical Co., Ltd.

Aﬂac Life Insurance Japan Ltd.
（アフラック）29

Sponsors

Illumina K.K.（イルミナ株式会社）
For more than 20 years, Illumina has aspired to improve
human health by unlocking the power of the genome. Our
initial products enabled researchers to explore DNA inan entirely new way. Now, with more than 3400 patents
worldwide and our sequencing-by-synthesis technology
being used to generate over 90% of the worldʼssequencing data, we are leading the way, one genomic
breakthrough at a time.

While the rate of progress continues to accelerate
exponentially as we move towards precision medicine,
we have only just begun to discover the true impactof genomics in areas we touch, including oncology,
reproductive health, genetic disease, agriculture,
microbiology, and beyond. Now, through innovation andcollaboration, we are enabling genomic breakthroughs
in immunotherapy, biomarker discovery, and therapy
selection. The opportunity to transform tumor proﬁling with
innovative assays that enable comprehensive genomic
profiling, new companion diagnostic development, andliquid biopsy inspires us to push boundaries and drive
innovation.
For more information please send us an email at
contactJPN@illumina.com

Eisai Co., Ltd

The Pediatric Brain Tumor Foundation
The Pediatric Brain Tumor Foundation is one of theworldʼs leading nonprofit organizations dedicated tochildren and teens with brain tumors. Our mission is
simple: Care. Cure. Thrive. We are committed to caring
for families along their journey, funding and ﬁnding cures
for all childhood brain tumors, and helping survivors andtheir families thrive. Our research investment strategy

is guided by our mission to maximize the number of lifechanging therapies moving from development throughto commercialization to find targeted treatments for all
children battling brain cancer. Since 1991, we havefunded more than $46 million in scientific discovery
through our Early Career Development awards, basic
and translational science projects, clinical trial researchand childhood cancer core infrastructure/education
opportunities. Together, we are helping move theneedle to find more effective treatments and a curefor all kids battling brain cancer. In addition, PBTF has
connected thousands of families each year with patientand family education, financial relief, and a thriving
community of support. A world without childhood brain
tumors is possible when we stand together to effectreal, meaningful change. We welcome all to support our
mission to Care. Cure. Thrive. at www.curethekids.org.

The Childhood Brain Tumor Foundation30

Sponsors
GENERAL SPONSORSKiTZ(the Hopp Children's Cancer Center at the NCT Heidelberg)
The Hopp Children's Cancer
Center Heidelberg (short:
KiTZ) is at the same timea therapy and research
center for oncological andhaematological diseases in childhood and adolescence.
More than 200 doctors, scientists and experts fromall medical fields are working together to scientificallyelucidate the biology of childhood cancer and severe
blood diseases and to closely link promising research
approaches with patient care - from diagnosis totreatment and aftercare. Children suﬀering from cancer,
especially those for whom no established treatment
options are available, are given an individual therapy planat the KiTZ. Additionally, we have established so-called
diagnostic platforms that allow for accurate diagnosis andtreatment decisions, both in initial diagnosis and relapses(INFORM, MNP-IntR or PTT2.0). Many young patients areable to take part in clinical trials and thus gain access to
new treatment options. The KiTZ thus assumes a model
function in the transfer of research findings from thelaboratory to the clinic.

Thermo Fisher Scientiﬁc
Thermo Fisher ScientificInc. is the world leader
in serving science, withannual revenue exceeding $25 billion. Our Mission isto enable our customers to make the world healthier,cleaner and safer. Whether our customers areaccelerating life sciences research, solving complex
analytical challenges, improving patient diagnostics andtherapies or increasing productivity in their laboratories,
we are here to support them. Our global team of morethan 75,000 colleagues delivers an unrivaled combinationof innovative technologies, purchasing convenience andpharmaceutical services through our industry-leading
brands, including Thermo Scientiﬁc, Applied Biosystems,
Invitrogen, Fisher Scientific, Unity Lab Services andPatheon.

Medical U&A, Inc.
Passionately Put the PatientFirst
Each one of our products is not something we just sell.
We believe in, and treasure the bonds between people
built up upon our products.
It is our mission to support every medical professional

who are dedicated to saving lives at the medical front
as well as to advance the health of patients and protect
their smiles.
Medical U&A strives to deliver the highest quality
products and services, contributing to, and playing anessential part in local community.

Canon Medical Systems Corporation
For more than 100 years,
Canon Medical Systems
has been at the cuttingedge of diagnostic imaging,creating healthcare solutions that can help enrich life foreveryone.
In line with our long-standing commitment to excellence,
we work hand-in-hand with leading clinical and academic
partners to bring you the solutions that can help make apositive diﬀerence to you and your patients.
Canon Medical Systems has a comprehensive portfolioof advanced medical imaging from diagnostic andinterventional imaging systems to healthcare IT solutions
for the wider healthcare enterprise.
Recognized as a world leader in innovation, Canon
Medical Systems continues to develop breakthroughtechnology and applications to support your imaging,
diagnostic and therapeutic needs, all while optimizing
patient outcomes.
・Whether thatʼs cutting-edge AI-assisted imaging,
intelligent healthcare IT, or even education and support,
our promise remains the same: we will always help
you put the wellbeing of your patients first.With Canon
Medical, true innovation is made possible.

31

Sponsors
THERABIOPHARMA Inc.
THERABIOPHARMA Inc.
has been established asa biotechnology venturecompany under thestrong collaboration with Kyoto University. Our aim is to
overcome the current fundamental issue of curcumin in
the application for cancers treatment by providing theadequate concentration of free form curcumin for the
carcinoma tissues to materialize curcuminʼs potential
efficacies most effectively. The innovative R&D coulddeliver the most advantageous curcumin prodrug formula
named curcumin monoglucuronide/TBP1901.
Curcumin, active form of TBP1901, showed the inhibitionof proliferation for glioblastoma cell lines, and TBP1901
clearly demonstrated signiﬁcant improvement of survival

for Glioblastoma orthotopic graft mice (median control 32
days vs TBP1901 (high) 59 days).
The mechanism of action of TBP1901 is thought thatit suppresses NF-κB activity through the inhibition ofproteasome, IKK, TAK1. Injectable TBP1901 achieved
10,000 times higher free-form curcumin in blood stream
than oral intake. This is the ﬁrst observation to attain theconcentration that reaches to show the antitumor activity
in vitro and in vivo particularly for the Glioblastoma.
In addition, 14-day repeated dose toxicity study has
been conducted in rats and cynomolgus monkeys anda sufficient margin of dose was found between thepharmacological effect and the safety. TBP1901 isthought to expect to be developed and clinically applied
as a glioblastoma-speciﬁc prodrug.

FUJIFILM Corporation
FUJIFILM group, Japan,
brings continuous innovation
with leading-edge, proprietary technologies by leveraging
its photography expertise into a broad range of industries
globally, including healthcare, graphic systems, highly
functional materials, optical devices, digital imaging
and document products. These products are based on
its extensive portfolio of chemical, mechanical, optical,
electronic and imaging technologies.
In the medical ﬁeld, now we are developing AI technology

to support diagnostic imaging, medical workflow,
equipment warranty and service by expanding the AI
technology under the “REiLI” brand; providing solutions
designed to meet market demands. Going forward, as
clinical information is increasingly viewed in the context
of big data, AI technology will be applied to develop
products that meet the different and challenging needsof the healthcare industry. Fujifilm aims to contributeto patient wellbeing through further improvements inhealthcare eﬃciency and quality.

FUJIFILM Medical Solutions Co.,Ltd.
FUJIFILM Medical Solutions'
ShadeQuest (image
information integration
system) is the best PACS for ﬁlmless operation, aiming tosupport the realization of "safe and secure medical care"and "medical care for patients" required by customers.
ShadeQuest realizes comfortable speed, excellent
operability, and optimal information management
environment by highly linking each system component
such as image storage, image display, and report
creation.

ShadeQuest also supports daily work in line with the workof each occupation involved in radiation therapy, such as
doctors, technicians, and nurses. In addition, information
written by medical professionals of various occupations
can be shared and confirmed, which is useful for therealization of patient-centered team medical care.
By linking online data with radiotherapy equipment,
treatment planning equipment, imaging equipment, etc.,
distributed data and image information is acquired andcentrally managed to build an integrated database ofradiotherapy information and the entire hospital.

The Uehara Memorial Foundation（上原記念生命科学財団）
The Uehara Memorial Foundation
was established in February
1985 to commemorate the 70 th anniversary of thefounding of Taisho Pharmaceutical Co., Ltd. and inmemory of Shokichi Uehara, former President andChairman of Taisho Pharmaceutical, who passed away

32

in March 1983. Since the fiscal year of 1985, theFoundationʼs income from basic assets has been mainly
utilized in providing grants for researchers, who are
engaging in life sciences, as well as for the recognitionof outstanding achievements in life science research(Uehara Award) and hosting of international symposia.

Sponsors
Denka Company Limited
Denka is a chemicals
manufacturer developing
business activities on a
global scale across a wide range of ﬁelds, from inorganicand organic chemicals, to electronic materials andpharmaceuticals.
The Life Innovation Division is expanding beyond
prevention and diagnosis into new ﬁelds such as cancer

treatment drugs and services for providing diagnostic
information.
In addition to influenza vaccine, diagnostic reagents,and macromolecular sodium hyaluronate preparations,the Life Innovation Division is working to expand thisbusiness field by providing products and services that
promote the health of people around the world.

St. Baldrick's Foundation
The St. Baldrickʼs Foundation
is a volunteer and donor
powered charity committed
to supporting the mostpromising research to find cures for childhood cancers
and give survivors long and healthy lives. Grants are
made for pediatric oncology research in many categories:
email Grants@StBaldricks.org for more information.

Nationwide Children's Hospital
Lead by pediatric neurooncologist
Dr. Maryam Fouladi andpediatric neurosurgeon
Dr. Jeffery Leonard, the Neuro-Oncology Program isengaged through leadership and clinical trials in every
major national neuro-oncology consortium including
CONNECT, NEXT, PBTC, PNOC, and COG.
The Neuro-Oncology team provides international
collaboration and support to peers in Central and SouthAmerica through the Global Outreach Program, the ﬁrst
of its kind in pediatric-oncology. Through the Head Start
4 protocol, Nationwide Children's leads over 50 sites
from around the world to improve the quality of survival

and cure rates for young children with primitive neuroectodermal tumors. And we continue to treat patientfamilies from around the globe including Canada, Poland,
Saudi Arabia, South Africa, China, and throughout theUnited States.
Named to the Top 10 Honor Roll on U.S. News & World
Reportʼs 2020-21 list of “Best Childrenʼs Hospitals,”Nationwide Childrenʼs Hospital is one of Americaʼs largest
not-for-proﬁt freestanding pediatric health care systems
providing wellness, preventive, diagnostic, treatment andrehabilitative care for infants, children and adolescents,
as well as adult patients with congenital disease.

Childrenʼs Brain Tumor Network
The Childrenʼs Brain Tumor
Networkʼs (CBTN) highlycommitted communityof expert researchers, clinicians, patient families, andsupport staff are dedicated to creating a world where
no child dies or suffers from a brain tumor. The CBTN
includes more than 20 member institutions located inEurope, Asia, Australia, and throughout the United States.
Discovering a cure for childhood brain cancer is ahuge challenge; one that needs the dedication, brain

power, and partnership of a global community to solve.
The CBTN is leading the charge to share resources,
discoveries, and expertise as broadly and as swiftly
as possible, to researchers anywhere on earth. Highlyannotated samples of tissue and data are available atno cost to researchers to empower scientiﬁc discovery
and collaboration across the scientific community. The
CBTNʼs collaborative mission is redeﬁning the traditional
research model by accelerating the pace of discovery for
all diagnosed children. To learn more, visit cbtn.org.

American Brain Tumor Association
Founded in 1973, theAmerican Brain Tumor
Association (ABTA) was
the first national nonprofit
organization dedicatedsolely to brain tumor
research.

The ABTA has since expanded its mission and now
provides comprehensive resources to support thecomplex needs of brain tumor patients and caregivers,
across all ages and tumor types, as well as the criticalfunding of research in the pursuit of breakthroughs inbrain tumor diagnoses, treatments and care.

33

Sponsors
DAIICHI SANKYO COMPANY, LIMITEDThe Preston Robert Tisch Brain Tumor Center
Established in 1937, The
Preston Robert TischBrain Tumor Center was
one of the first brain
tumor research andclinical programs in the United States. Since then, it
has advanced to become one of the best pediatric andadult neuro-oncology programs in the world̶leading
the way in comprehensive care that combines researchbreakthroughs, clinical trials and the newest therapies.
The National Cancer Institute (NCI) has given our center
the highest rating of “outstanding” for each of the last 15
years.

Our patients are the reason we strive to deliver hopeevery day. They come here for the most advanced
treatments. Often these are therapies that are notavailable anywhere else. Our center sees up to 900 new
adult brain tumor patients and up to 75 new pediatricbrain tumor patients per year from across the country
and around the world. At the core of our successlies the commitment of countless physicians, nurses,
researchers and staﬀ ‒ all with the goal to stand with ourpatients and families in the ﬁght against brain tumors. We
offer aggressive research and passionate care with adetermination and clear focus to ﬁght the disease.

S ＆ Brain Corporation
Business :Established in 2008, head office is located in Urayasu
city in Chiba prefecture, Japan.

Development of domestic instrument, mainly
for Neuro Surgery

Main Product :Brand :

Titanium PlateSP Plate（sterile）

CHARLES RIVER LABORATORIES JAPAN, INC.
[Our passion comes fromour commitment to helping
you help others.]
At Charles River, we are passionate about our role in
improving the quality of peopleʼs lives. Our mission, ourexcellent science and our strong sense of purpose guides
us in all that we do, and we approach each day with theknowledge that our work helps to improve the health andwell-being of many across the globe.
[Oncology & Immuno-Oncology Studies]
To reach the clinic in record time, itʼs vital to test

your oncology therapies in systems that reflect thedisease seen in humans. Charles River oﬀers a range oftranslational oncology studies, including in vitro assays
and in vivo models, that mirror human cancers. Whether
you want to test your therapy in a cell biology assay
consisting of the elements of the tumor microenvironment
or in models using real patient tissue, we can help.
[Virtual Exhibit]
Virtual Exhibit booths are now available for you to learn
more about our research portfolio. Please visit our Virtual
Exhibition.

AS ONE CORPORATION

NanoString Technologies, Inc.
NanoString Technologies(NASDAQ: NSTG) is a
publicly held provider of life
science tools for translational research. The company's
technology enables a wide variety of basic research andtranslational medicine applications.
NanoString's products are based on a novel digital
molecular barcoding technology invented at the Institutefor Systems Biology (ISB) in Seattle under direction of
Dr. Leroy Hood. The company was founded in 2003
with an exclusive license to develop and market thetechnology. In 2008, NanoString launched its firstcommercial instrument system and began international

34

sales operations with its ﬁrst multiplexed assays for gene
expression analysis. In 2010, the company launched new
applications for the system to support microRNA analysis
and copy number variation detection. In 2019, thecompany launched the GeoMx™ Digital Spatial Profiler
enabling highly-multiplexed spatial profiling of RNA andprotein targets in a variety of sample types, including
FFPE tissue sections.
AS ONE is NanoString's distributor in Japan, and today,in addition to exhibiting NanoString products, we are
exhibiting 2D barcode tubes for sample management andrelated products.

Sponsors
Collaborative Ependymoma Research Network Foundation
The Collaborative
Ependymoma ResearchN e t w o r k ( C E R N )Foundation, a designated program of the National
Brain Tumor Society, is dedicated to improving the
lives of children and adults worldwide diagnosed withependymoma. The CERN Foundation continues toadvance ependymoma research by supporting scientiﬁcfellowships, clinical trials, and sponsoring professional
conferences and symposia. We strive to bring awarenessto the rare disease and improve the outcome and careof patients through education, referral support, andsupported research eﬀorts.

Sumitomo Dainippon Pharma Co., Ltd.

Carl Zeiss Meditec AG
Carl Zeiss Meditec AG is
one of the worldʼs leading
medical technology
companies. The Company
supplies innovative technologies and applicationoriented solutions designed to help doctors improve
the quality of life of their patients. The Company offers
complete solutions, including implants and consumables,
to diagnose and treat eye diseases. The Company
creates innovative visualization solutions in the field of
microsurgery.
ZEISS Surgical Microscopes continuing to support you in
advancing surgical visualization.
Our flagship visualization system, KINEVO® 900 fromZEISS is designed to deliver more functionalities than any
surgical microscope today. ZEISS KINEVO 900 combines

digital and optical visualization modalities, oﬀers a unique
Micro-Inspection Tool and will impress you with its
Surgeon-Controlled Robotics.
1.Surgeon-Controlled Robotics adds a complete newlevel of ease to precise positioning. Imagine being able
to focus and move around a structure to visualize thetargeted anatomy.
2.The Digital Hybrid Visualization with integrated 4K
technology of ZEISS KINEVO 900 welcomes you toa world of heads-up ocular-free surgery, giving you
freedom of movement.
3.The unique, proprietary Micro-Inspection Tool fromZEISS complements intraoperative microsurgicalvisualization, enabling you to discover unexplored
areas during the surgical intervention without additional
footprint.

Aqua Clara, inc

東京南ロータリークラブ
The Rotary Club of Tokyo-South
Rotary Club of Tokyo South,
which has a history of over
60 years, was establishedin 1950 after became independent from Rotary Clubof Tokyo. Tokujiro Kanamori, who was deeply involvedin the establishment of current Japanese constitution,
assumed the Club as a First chairman. Since then, we
have been inheriting his idea of liberal as a tradition of

our Club.
Presently, there are over 200 members in our club.
Registration fee (Category: Delegate 2) for clinicians,
researchers and industry members who are from the low/
lower-middle income countries assigned by the WorldBank Group are partially supported by the donations fromThe Rotary Club of Tokyo South Fellowship.

東京シティ日本橋ロータリークラブ
The Rotary Club of Tokyo City Nihonbashi
Our club was born in 1991
from the Rotary Club of Nihonbashi East, 68th club in theth2750 District and 1949 club in Japan.
And involved in the Ginza-Nihonbashi Group of the 2750

District.
Our regular meeting is held on Friday 12:30a.m. at theRoyal Park Hotel（2-1-1 Kakigara-chou Chuou-ward
Tokyo Met.）

35

Sponsors
the Tokyo Biochemical Research Foundation（公益財団法人東京生化学研究会）
We are engaged in thefollowing activities tosupport innovative researchon pharmaceutical products.
● Research grants and incentives● Invitation of overseas researchers and provision ofscholarships● Holding symposiums and academic conferences● Reward to researchers● Subsidy for dispatching researchers to international
conferences

東京医科歯科大学脳神経外科同門会
The Tokyo Medical
and Dental University
Neurosurgery Alumni Society has been established in
1995 to support professional, scientific, and medical
interactions among the members. Over the past five
decades, about 200 of our members have built successfulcareers at academic, research and medical facilities
across the nation. It is our great pleasure that Dr. Koichi
Ichimura, who is our alumni, will serve as the chairman of
ISPNO2020, and we sincerely wish the symposium will be
fruitful for all the participants.

The Japan Pediatric Brain Tumor Research Fund
（小児脳腫瘍研究支援委員会）

今村

純一郎

大野

喜久郎

Keiji Sano Lectureship第 36 回日本脳腫瘍学会学術集会
第 37 回日本脳腫瘍学会学術集会
ながしま脳神経・頭痛クリニック
医療法人社団美心会
社会医療法人北斗
社会医療法人社団 森山医会
ユーシービージャパン 株式会社株式会社エスアールエル
医療法人社団川善会六地蔵クリニック
医療法人千清會
合同会社 KIIN
合同会社 Be First

小笠原

陽

金子

勝一

小柳

省一郎

酒葉

乃里子

清水

一秀

菅原

高志

鈴木

龍太

露無

松平

松井

秀文

Noboru Minowa
山本徳治郎

東京日本橋ロータリークラブ
東京新橋ロータリークラブ
東京銀座ロータリークラブ
東京シティ日本橋ロータリー クラブ
ライオンズクラブ国際協会 330-A 地区
東京あけぼのロータリークラブ
（敬称略）

36

Sponsors
ISPNO2020 日本製薬団体連合会寄付(List of Sponsors through the Federation of Pharmaceutical Manufacturers' Associations of JAPAN)

旭化成ファーマ株式会社

武田薬品工業株式会社

あすか製薬株式会社

田辺三菱製薬株式会社

アステラス製薬株式会社

中外製薬株式会社

アストラゼネカ株式会社

株式会社ツムラアルフレッサファーマ株式会社

帝人ファーマ株式会社

栄研化学株式会社

テルモ株式会社

エーザイ株式会社

トーアエイヨー株式会社

エスエス製薬株式会社

東和薬品株式会社

MSD 株式会社

鳥居薬品株式会社

大塚製薬株式会社

日本化薬株式会社

株式会社大塚製薬工場

日本ケミファ株式会社

小野薬品工業株式会社

日本新薬株式会社

科研製薬株式会社

日本製薬株式会社

キッセイ薬品工業株式会社

日本臓器製薬株式会社

杏林製薬株式会社

日本たばこ産業株式会社

協和キリン株式会社

日本ベーリンガーインゲルハイム株式会社

クラシエ製薬株式会社

ニプロファーマ株式会社

興和株式会社

バイエル薬品株式会社

佐藤製薬株式会社

扶桑薬品工業株式会社

サノフィ株式会社

ブリストル・マイヤーズ スクイブ株式会社

沢井製薬株式会社

丸石製薬株式会社

参天製薬株式会社

マルホ株式会社

株式会社三和化学研究所

株式会社ミノファーゲン製薬

塩野義製薬株式会社

Meiji Seika ファルマ株式会社

ゼリア新薬工業株式会社

持田製薬株式会社

第一三共株式会社

株式会社ヤクルト本社

大正製薬株式会社

ロート製薬株式会社

大日本住友製薬株式会社

わかもと製薬株式会社

大鵬薬品工業株式会社（五十音順）

37

SaveSavethe the
Date:
June
Date:
June13-15,
13-15, 2022!
2022!

Copyright Mediaserver
Copyright Mediaserver
Hamburg Hamburg

We are looking forward to welcoming you to the 20th International Symposium
on Pediatric Neuro-Oncology - June 13-15, 2022 - Hamburg, Germany
Chairs: Stefan Rutkowski, Hamburg
ChairsStefan Pfister, Heidelberg
Venue:: Congress Center Hamburg
VenueCT_Tin_filter_AD_A5Y_1C_190507_out.indd 1

2019/05/07 11:08

「攻め」と「守り」を巧みに操る
Masterful Maneuverability to Conquer and Protect

超音波吸引器CUSA Clarity
®

製造販売元

販売名：超音波手術器

Integra Japan 株式会社

承認番号：23000BZX00065000〒107-0052

東京都港区赤坂1丁目 7 番 1号 赤坂榎坂ビル

TEL: 03-6809-0235

FAX: 03-6809-0236

CUSA Clarity

クラス分類：高度管理医療機器 クラスⅢ
特定保守管理医療機器

レザフィリン+PDレーザーBT（H127×W90）

要返却※「効能・効果」、「 用法・用量」、「 効能・効果に関連する使用上の注意」「、用法・用量に関連する使用上の注意」「、禁忌を含む使用上の注意」など、
詳細は製品の添付文書等をご参照ください。

作成：2020.11

CONNECTING BRAINSAROUND THE WORLDThe Robert Connor Dawes Foundation works closelywith organisations and researchers around the world tofast-track research funding and ultimately, improvetreatment options.
We believe more brains are better than one, and we're
proud to fund crucial research collaborations
including, The AIM BRAIN Project, in partnershipwith ANC  and D F in ermany, and a
CERN Fellowship currently underway in Cambridge.
Learn more at Rcdfoundation.org
SUPPORTING PEDIATRIC BRAIN CANCER
MATTERS IN THE AREAS OF RESEARCH,
CARE & DEVELOPMENTROBERT CONNOR DAWES FOUNDATIONThe Arnold & Winnie Palmer
Foundation champions the legacy of
our founders. Through grantmaking
and initiatives, we continue Arnold
and Winnie’s devotion to youth –encouraging strong character andsupporting children facing healthchallenges – and honor theircommitment to nature and its ability
to enrich and heal us.
www.PalmerFoundation.org

Practical Implementation of
DNA Methylation and CNV
Based CNS Tumor Testing(Virtual Peer-to-Peer Meeting)

C

M

Y

CM

Presenters:

MY

Felix Sahm, MD, PhD

Eric Vail, MD

David Solomon, MD, PhD

Andreas von Deimling, MD

German Cancer Research Center (DKFZ),
Heidelberg, Germany

UCSF Clinical Cancer Genomics
Laboratory, USA

Cedars-Sinai, USA

CY

CMY

German Cancer Research Center (DKFZ),K
Heidelberg, Germany

https://jp.illumina.com/events/seminars/2020/
dna-methylation-peer-to-peer.html

Doing everything
we can for patients
who are waiting
AbbVie GK

Illumina K.K.
Mita Bellju Building 22F
5-36-7 Shiba, Minato-ku, Tokyo 108-0014, Japan
jp.illumina.com

3-1-21 Shibaura, Minato-ku
Tokyo 108-0023, Japan
https://www.abbvie.co.jp/